CN115210372A - 一种制备定点修饰的长链rna的方法 - Google Patents
一种制备定点修饰的长链rna的方法 Download PDFInfo
- Publication number
- CN115210372A CN115210372A CN202180001879.XA CN202180001879A CN115210372A CN 115210372 A CN115210372 A CN 115210372A CN 202180001879 A CN202180001879 A CN 202180001879A CN 115210372 A CN115210372 A CN 115210372A
- Authority
- CN
- China
- Prior art keywords
- rna
- nucleic acid
- fragment
- strand
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 529
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 45
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 42
- 238000000137 annealing Methods 0.000 claims abstract description 18
- 238000004925 denaturation Methods 0.000 claims abstract description 14
- 230000036425 denaturation Effects 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims description 584
- 230000000295 complement effect Effects 0.000 claims description 172
- 230000004048 modification Effects 0.000 claims description 56
- 238000012986 modification Methods 0.000 claims description 56
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 239000002243 precursor Substances 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000002194 synthesizing effect Effects 0.000 claims description 17
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 14
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 14
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 150000003290 ribose derivatives Chemical class 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 125000005642 phosphothioate group Chemical group 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229930010555 Inosine Natural products 0.000 claims description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 229960003786 inosine Drugs 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 24
- 238000007385 chemical modification Methods 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 58
- 102000053602 DNA Human genes 0.000 description 58
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000000429 assembly Methods 0.000 description 11
- 230000000712 assembly Effects 0.000 description 11
- 238000010532 solid phase synthesis reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 8
- 101710086015 RNA ligase Proteins 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 230000006819 RNA synthesis Effects 0.000 description 6
- 108091028664 Ribonucleotide Proteins 0.000 description 6
- 239000005547 deoxyribonucleotide Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002336 ribonucleotide Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001089723 Metaphycus omega Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 101710188535 RNA ligase 2 Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 101710204104 RNA-editing ligase 2, mitochondrial Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Natural products CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
Landscapes
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
提供了一种制备长链RNA的方法，包括：合成步骤、退火步骤，和连接步骤。所述制备长链RNA的方法通过对第一链的RNA片段和第二链中核酸片段的设计，能够实现对长链RNA中任意精确位点的化学修饰，使长链RNA获得提高的稳定性和改善的免疫原性等性能。通过该制备方法能够得到由连续化的单链RNA与片段化的单链核酸链互补形成的双链组装体，双链组装体仅需通过简单变性即可得到单链的长链RNA，有效简化了目前长链RNA的合成步骤，提高了合成效率，适合于工业化大规模制备。
Description
PCT国内申请，说明书已公开。
Claims (16)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021101852511 | 2021-02-10 | ||
| CN202110185251 | 2021-02-10 | ||
| PCT/CN2021/098422 WO2022170705A1 (zh) | 2021-02-10 | 2021-06-04 | 一种制备定点修饰的长链rna的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115210372A true CN115210372A (zh) | 2022-10-18 |
Family
ID=82837485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180001879.XA Pending CN115210372A (zh) | 2021-02-10 | 2021-06-04 | 一种制备定点修饰的长链rna的方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115210372A (zh) |
| WO (1) | WO2022170705A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0718409A3 (en) * | 1994-12-22 | 1999-02-03 | Hitachi, Ltd. | DNA preparation method |
| EP1531183A1 (en) * | 2003-11-14 | 2005-05-18 | bioMérieux BV | Method for amplification of RNA sequences |
| CN103993002A (zh) * | 2013-02-19 | 2014-08-20 | 百奥迈科生物技术有限公司 | 一种大规模合成长链rna药物的生产新工艺 |
| CN103865922A (zh) * | 2014-03-25 | 2014-06-18 | 中国海洋大学 | 一种rna的制备方法 |
| SG11201610168YA (en) * | 2014-05-16 | 2017-01-27 | Illumina Inc | Nucleic acid synthesis techniques |
-
2021
- 2021-06-04 CN CN202180001879.XA patent/CN115210372A/zh active Pending
- 2021-06-04 WO PCT/CN2021/098422 patent/WO2022170705A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022170705A1 (zh) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3323890A1 (en) | Method for inducing site-specific rna mutations, target editing guide rna used in method, and target rna target editing guide rna complex | |
| Moon et al. | Improving CRISPR genome editing by engineering guide RNAs | |
| EP1836302B1 (en) | Ligation-based rna amplification | |
| EP3481838B1 (en) | Novel processes for the production of oligonucleotides | |
| EP3394292A1 (en) | Methods of library construction for polynucleotide sequencing | |
| JP7065970B2 (ja) | オリゴヌクレオチドの産生のための新規プロセス | |
| WO2023115786A1 (zh) | 一种制备双链rna的方法 | |
| WO2022241045A1 (en) | Modified mrna, modified non-coding rna, and uses thereof | |
| CN112424375A (zh) | 用于寡核苷酸治疗剂的大规模平行发现方法 | |
| CN107338245B (zh) | 一种大规模制备单链dna的方法 | |
| CN102191246B (zh) | 多靶标干扰核酸分子及其应用 | |
| US20230357790A1 (en) | Self-targeting expression vector | |
| US20220298507A1 (en) | Compositions and methods for rna interference | |
| WO2018232038A1 (en) | Methods of library construction for target polynucleotides | |
| CN115210372A (zh) | 一种制备定点修饰的长链rna的方法 | |
| CN112111544B (zh) | 提高单链dna连接效率的方法 | |
| CN114592022A (zh) | 一种基于dna模板的长链tna合成方法 | |
| JP7333171B2 (ja) | Ｒｎａ検出方法、ｒｎａ検出用核酸及びｒｎａ検出用キット | |
| CN102199603B (zh) | 多靶位干扰rna分子及其应用 | |
| CN112941147B (zh) | 一种高保真靶标基因建库方法及其试剂盒 | |
| CN115605590A (zh) | 一种制备定点修饰的长链dna的方法 | |
| Dolinnaya et al. | Chemical ligation as a method for the assembly of double-stranded nucleic acids: Modifications and local structure studies | |
| Sabat et al. | Template-dependent DNA ligation for the synthesis of modified oligonucleotides | |
| Emehiser | Exploring Double-Strand DNA-Targeting Strategies | |
| TW202405168A (zh) | 製造含有寡核苷酸之聚核苷酸的新穎方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |